Huang 2016.

Methods	Study design: Randomised clinical trial Study duration: February 2013 to September 2014 Duration of follow‐up: 15 months Setting: Hospital
Participants	Inclusion criteria: Diagnosed as middle or advanced HCC Age (mean ± SD): TACE + RFA: 42.6 ± 4.8 years; TACE alone: 41.3 ± 4.4 years Male (n/total): TACE + RFA: 52/90; TACE alone: 49/90
Interventions	TACE + RFA group (n = 90): TACE: Chemotherapeutic drugs: theprubicin 450 mg RFA: The interval between TACE and RFA was 3‐5 weeks. CT‐guided RFA TACE group (n = 90): Chemotherapeutic drugs: theprubicin 450 mg
Outcomes	Serum level of AFP and CA‐199 Survival rate at 5, 10, and 15 months after treatment Recurrence rate at 15 months after treatment
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.